Question 1

Does ACTH 4-10 raise cortisol levels?

Accepted Answer

No. This is the key pharmacological distinction of ACTH 4-10. The steroidogenic (cortisol-stimulating) activity of ACTH resides in the N-terminal 1-24 sequence, with the 1-4 region being critical for adrenal receptor activation. The 4-10 fragment lacks this activity entirely and does not stimulate the adrenal cortex, raise cortisol, or activate the HPA axis. This allows the cognitive effects to be studied and utilized independently of stress hormone responses.

Question 2

What human evidence exists for ACTH 4-10's cognitive effects?

Accepted Answer

Multiple human studies were conducted primarily between the 1970s and 1990s, largely by Dutch researchers including De Wied, Sandman, and colleagues. These studies showed that ACTH 4-10 improves selective attention (particularly in visual attention tasks), enhances short-term memory consolidation, accelerates information processing speed, and increases motivation. Studies were conducted in healthy volunteers, elderly subjects with mild cognitive decline, and patients recovering from brain injury. While results were generally positive, most studies had small sample sizes and would not meet current standards for clinical trial rigor.

Question 3

How does ACTH 4-10 relate to Semax?

Accepted Answer

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic analog of ACTH 4-10 developed in Russia, where positions 8-10 (Arg-Trp-Gly) of ACTH 4-10 have been replaced with Pro-Gly-Pro to improve metabolic stability. Semax retains and enhances the nootropic properties of ACTH 4-10 while having a significantly longer half-life. Semax has been approved in Russia and several former Soviet states as a nootropic drug, making it the most clinically advanced derivative of the ACTH 4-10 sequence.

Question 4

What is Org 2766 and how does it relate to ACTH 4-10?

Accepted Answer

Org 2766 (Met(O2)-Glu-His-Phe-D-Lys-Phe) is a synthetic analog of ACTH 4-9 (a subset of the 4-10 sequence) developed by Organon that is approximately 1000-fold more potent than native ACTH 4-10 in behavioral assays. It was studied clinically for neuroprotection in chemotherapy-induced peripheral neuropathy and for cognitive enhancement. While Org 2766 showed promising results in some trials, development was ultimately discontinued. Its history demonstrates the pharmacological potential of the ACTH 4-10 core sequence.

Question 5

How is ACTH 4-10 typically administered?

Accepted Answer

In published human studies, ACTH 4-10 and its analogs have been administered via intramuscular injection, subcutaneous injection, and intranasal spray. Intranasal delivery is of particular interest because it provides more direct access to the CNS while avoiding first-pass hepatic metabolism. The peptide's relatively short plasma half-life (15-20 minutes) is less of a limitation than it might seem, because the cognitive effects appear to be triggered by transient receptor engagement and persist well beyond the peptide's circulation time.

Question 6

What are the side effects of ACTH 4-10?

Accepted Answer

ACTH 4-10 has shown a favorable safety profile in published human studies. Because it lacks steroidogenic activity, it does not produce cortisol-related side effects such as immune suppression, metabolic disruption, or adrenal axis perturbation. Reported side effects have been minimal and include occasional mild headache, transient facial flushing (likely melanocortin-related), and injection site reactions. No serious adverse events have been reported in the published clinical literature. However, long-term safety data is limited.

Question 7

Can ACTH 4-10 be combined with other nootropic peptides?

Accepted Answer

ACTH 4-10 has a distinct mechanism (melanocortin receptor modulation, catecholamine facilitation) from most other nootropic peptides, making it theoretically combinable with peptides that work through different pathways. However, because ACTH 4-10 shares a related sequence with Semax (which is essentially a stabilized analog), combining the two would be redundant. Combining ACTH 4-10 with peptides that work through different mechanisms — such as Selank (GABAergic), Dihexa (HGF/c-Met), or PE-22-28 (TREK-1) — is more pharmacologically rational, though no combination studies have been published.

Question 8

Why isn't ACTH 4-10 more widely used if it has human data?

Accepted Answer

Several factors explain its limited adoption: (1) the human studies, while positive, were mostly small and conducted decades ago without modern trial design standards; (2) the peptide's short half-life makes it inconvenient for chronic use; (3) more stable analogs like Semax and Org 2766 largely superseded it in research; (4) no pharmaceutical company has pursued FDA approval; and (5) the general regulatory and commercial challenges facing peptide nootropics have prevented clinical development. The scientific foundation is reasonable, but the practical pathway to approved therapeutic use has not been pursued.

Question 9

Does ACTH 4-10 affect mood or motivation?

Accepted Answer

Yes, though the effects are subtle compared to dedicated anxiolytic or antidepressant compounds. Human studies have reported increased motivation, improved concentration under demanding conditions, and enhanced goal-directed behavior following ACTH 4-10 administration. These effects are thought to be mediated by facilitation of dopaminergic and noradrenergic neurotransmission rather than direct mood-altering mechanisms. ACTH 4-10 does not produce euphoria, stimulant-like effects, or anxiolysis — its motivational effects are better described as enhanced engagement with cognitive tasks.

Question 10

Is ACTH 4-10 banned in competitive sports?

Accepted Answer

ACTH 4-10 is not specifically listed on the WADA Prohibited List, which names full-length ACTH and its steroidogenic analogs (due to their ability to stimulate cortisol production). Since ACTH 4-10 lacks steroidogenic activity, it does not fall under the same rationale for prohibition. However, WADA's list includes catch-all categories for substances with pharmacological activity, and athletes should consult their sport's specific anti-doping guidance. The regulatory interpretation of peptide fragments can evolve.

Origin / Manufacturer	Synthetic
Active Components	ACTH 4-10 heptapeptideBacteriostatic water (for reconstitution)
Storage	Lyophilized: room temperature. Reconstituted: 2–8°C
Shelf Life	Lyophilized 24+ months; reconstituted 30 days refrigerated
Form Factor	Lyophilized powder (5 mg vial)

ACTH 4-10

Specifications

Frequently Asked Questions

Related Peptides

Dihexa

NA-Selank Amidate

Selank

Semax